Zacks Research Analysts Lower Earnings Estimates for EW

Edwards Lifesciences Co. (NYSE:EW - Free Report) - Stock analysts at Zacks Research dropped their Q1 2025 EPS estimates for Edwards Lifesciences in a research report issued on Thursday, November 14th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings per share of $0.59 for the quarter, down from their previous estimate of $0.69. The consensus estimate for Edwards Lifesciences' current full-year earnings is $2.57 per share. Zacks Research also issued estimates for Edwards Lifesciences' Q2 2025 earnings at $0.62 EPS, Q3 2025 earnings at $0.59 EPS, Q4 2025 earnings at $0.64 EPS, Q1 2026 earnings at $0.67 EPS, Q2 2026 earnings at $0.70 EPS and Q3 2026 earnings at $0.71 EPS.

EW has been the topic of a number of other reports. Robert W. Baird decreased their target price on Edwards Lifesciences from $73.00 to $68.00 and set a "neutral" rating on the stock in a report on Friday, October 25th. Canaccord Genuity Group decreased their price objective on shares of Edwards Lifesciences from $66.00 to $63.00 and set a "hold" rating on the stock in a report on Friday, October 25th. Oppenheimer restated an "outperform" rating and set a $90.00 target price on shares of Edwards Lifesciences in a research note on Thursday, September 12th. JPMorgan Chase & Co. lifted their target price on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a "neutral" rating in a report on Friday, October 25th. Finally, Morgan Stanley reissued an "equal weight" rating and issued a $70.00 price target on shares of Edwards Lifesciences in a report on Friday, October 11th. Seventeen equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $75.67.

Edwards Lifesciences Stock Performance

NYSE EW traded up $2.13 during trading on Monday, reaching $69.89. 7,021,039 shares of the company's stock were exchanged, compared to its average volume of 4,654,247. Edwards Lifesciences has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The stock has a market capitalization of $41.22 billion, a P/E ratio of 9.78, a PEG ratio of 3.81 and a beta of 1.12. The business has a 50 day moving average price of $67.44 and a 200-day moving average price of $76.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same period in the previous year, the business earned $0.59 EPS. Edwards Lifesciences's revenue for the quarter was up 8.9% compared to the same quarter last year.

Institutional Trading of Edwards Lifesciences

Hedge funds have recently added to or reduced their stakes in the stock. Avantax Advisory Services Inc. grew its position in Edwards Lifesciences by 4.1% during the 1st quarter. Avantax Advisory Services Inc. now owns 6,887 shares of the medical research company's stock worth $658,000 after acquiring an additional 272 shares during the last quarter. M&G Plc acquired a new position in shares of Edwards Lifesciences in the first quarter valued at approximately $853,000. O Shaughnessy Asset Management LLC increased its stake in shares of Edwards Lifesciences by 27.3% in the first quarter. O Shaughnessy Asset Management LLC now owns 36,897 shares of the medical research company's stock valued at $3,526,000 after buying an additional 7,918 shares during the period. Seven Eight Capital LP raised its holdings in Edwards Lifesciences by 2.6% in the 1st quarter. Seven Eight Capital LP now owns 17,613 shares of the medical research company's stock valued at $1,683,000 after buying an additional 441 shares during the last quarter. Finally, Lake Street Advisors Group LLC boosted its position in Edwards Lifesciences by 36.2% during the 1st quarter. Lake Street Advisors Group LLC now owns 3,573 shares of the medical research company's stock worth $341,000 after buying an additional 950 shares during the period. Institutional investors and hedge funds own 79.46% of the company's stock.

Insider Buying and Selling

In other news, VP Daveen Chopra sold 1,250 shares of the stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now owns 29,333 shares of the company's stock, valued at approximately $2,051,843.35. This represents a 4.09 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 41,250 shares of company stock worth $2,744,438. Corporate insiders own 1.29% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.